- Home
- VVPR vs MAIA Comparison
VVPR vs MAIA Comparison
Compare VVPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVPR | MAIA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 44.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VVPR | MAIA |
|---|---|---|
| Price | $2.82 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 498.2K | ★ 873.7K |
| Earning Date | 09-02-2023 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 281.25 | N/A |
| 52 Week Low | $0.62 | $0.87 |
| 52 Week High | $8.88 | $2.74 |
Technical Indicators
Market Signals| Indicator | VVPR | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 56.22 |
| Support Level | $2.37 | $1.07 |
| Resistance Level | $2.78 | $1.25 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 60.00 | 54.41 |
Price Performance
Historical ComparisonAbout VVPR VivoPower International PLC
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.